Bizarre Patents
Self Containing Enclosure for Protection from Killer Bees
A self contained protective enclosure with an opening for entry and egress and a screen for ventilation and viewing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6380458 | Cell-lineage specific expression in transgenic zebrafish Disclosed are transgenic fish, and a method of making transgenic fish, which express transgenes in stable and predictable tissue- or developmentally-specific patterns. The transgenic fish contain transgene constructs with homologous expression sequences. ... | 04/30/2002 |
| 6376743 | Mammalian transgenesis by intracytoplasmic sperm injection Coinjection of unfertilized mouse oocytes with sperm heads and exogenous nucleic acid encoding a transgene results in transgene-expressing embryos, reflecting nucleic acid-sperm head association before coinjection. Nonselective transfer to surrogate mothe... | 04/23/2002 |
| 6372957 | Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca++ stimulation of the hyp... | 04/16/2002 |
| 6372956 | Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor The present invention features transgenic rodent models for HIV, wherein the transgenic rodent or transgenic rodent cell has incorporated into its genome genes encoding a human CD4 receptor and a human chemokine receptor. In particular the invention relat... | 04/16/2002 |
| 6374130 | Methods for tracking the progression of Alzheimer's disease identifying treatment using transgenic mice A method of screening pharmaceutical drugs, gene therapies, vaccines, dietary supplements, behavioral and environmental therapies and other clinical treatments for potential efficacy in the treatment of Alzheimer's disease in humans. The method includes s... | 04/16/2002 |
| 6372958 | Transgenic mouse with endogenous endoglin gene disruption Transgenic mice are genetically engineered for a deficiency in endoglin production. These mice may have a homozygous or hemizygous disruption of the endogenous endoglin gene. Homozygous mice exhibit a lack of endoglin production. The failure to produce en... | 04/16/2002 |
| 6369295 | Uses of transgenic mouse containing a type X collagen mutant This invention provides an isolated DNA comprising the sequence which codes for a mutated collagen X or a portion thereof wherein the expression of the DNA regulates bone growth. This invention provides a polypeptide encoded by the isolated DNA comprising... | 04/09/2002 |
| 6365796 | Transgenic UCP2 knockout mouse and use thereof The present invention provides a transgenic non-human mammal which lacks a functional UCP2 gene. The UCP-2 deficient transgenic knockout mammal described herein provides a source of cells and animals useful to practice methods for the identification and/o... | 04/02/2002 |
| 6359194 | Compositions and methods for the treatment and diagnosis of cardiovascular disease The present invention is based on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice ar... | 03/19/2002 |
| 6353151 | Transgenic model for heart failure The present invention discloses a transgenic mouse that is a model for congestive heart failure. The disclosed mouse is a subset of a transgenic mouse line that is a model for hypertrophic cardiomyopathy. Also disclosed are a recombinant nucleic acid mole... | 03/05/2002 |
| 6353152 | Corticotropin releasing factor receptor 2 deficient mice and uses thereof The present invention provides transgenic mice deficient in corticotropin releasing factor receptor 2. Corticotropin releasing factor is a critical integrator of the hypothalamic-pituitary-adrenal axis in response to stress. CRF and its related molecule u... | 03/05/2002 |
| 6350932 | Vitamin D receptor ablated mice A transgenic mouse containing disruptions in both vitamin D alleles and lacking vitamin D receptor activity is described. The transgenic mouse displays perioral and periorbital alopecia, hypocalcemia, hypophosphatemia, and bone demineralization. The trans... | 02/26/2002 |
| 6331658 | Genetically engineered mammals for use as organ donors Methods to manipulate animals such as pigs, and the animals and tissues thereby derived, to reduce their immunogenicity following implantation into humans, are described. These methods are based on the discovery that certain carbohydrate structures on pig... | 12/18/2001 |
| 6329566 | Methods for the detection, treatment, and prevention of neurodegeneration In general, the invention provides methods for identifying genes involved in neurodegeneration and therapeutics for treating animals with a neurodegenerative disease. Methods and kits for the detection of compounds which enhance neuroprotection and diagno... | 12/11/2001 |
| 6326526 | Melatonin receptor-deficient mice and uses thereof Disclosed are mice containing a targeted disruption of various melatonin receptor subtypes, and methods of using the mice to identify agonists and antagonists of melatonin.... | 12/04/2001 |
| 6316692 | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies A composition for in vivo transfection of non-human mammalian male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral componen... | 11/13/2001 |
| 6316690 | Non-mammalian transgenic animal model for cellular proliferative diseases Non-mammalian, transgenic animals, e.g. flies, that exhibit neoplastic phenotypes, i.e. spontaneously produce metastatic tumors, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having act... | 11/13/2001 |
| 6316689 | 25-hydroxyvitamin D3 24-hydroylase transgenic rats The transgenic animal of this invention can be used as an animal model for renal disease, bone disease, joint disease, pulmonary disease, hyperlipidemia, arteriosclerosis, cardiac disease, diabetes, obesity, digestive organ disease, infectious disease, al... | 11/13/2001 |
| 6316693 | Transgenic mouse model for fatty acid transport The present invention is directed toward a transgenic mouse comprised of germ cells and somatic cells which contain a recombinant CD36 gene operatively linked to a muscle creatine kinase promoter. Overexpression of the reconbinant CD36 gene in muscle tiss... | 11/13/2001 |
| 6313373 | Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides ... | 11/06/2001 |
| 6310270 | Endothelial NOS knockout mice and methods of use This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic ... | 10/30/2001 |
| 6309848 | Human xenografts for microbicide testing and anatomical modeling A method for screening candidate antimicrobial compounds is described that utilizes a human vaginal xenograft engrafted in a non-human host. The method may be performed by using pathogen inoculated human vaginal xenografts in order to screen a wide range ... | 10/30/2001 |
| 6307121 | Bacteriophage-based transgenic fish for mutation detection The present invention provides transgenic fish whose somatic and germ cells contain a genomically integrated bacteriophage lambda-derived transgene construct. The transgene construct can include an excisable test nucleic acid sequence containing a heterol... | 10/23/2001 |
| 6307122 | Infection of human neural xenografts Immunocompromised or immunosuppressed non-primate chimeric mammalian hosts comprising a neuronal graft in the eye are provided for studying various events associated with humans. Particularly, the chimeric host may have solely human fetal neuronal xenogra... | 10/23/2001 |
| 6300129 | Transgenic non-human animals for producing heterologous antibodies The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.... | 10/09/2001 |
| 6300540 | Transgenic mouse expressing an APP-FAD DNA sequence Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding ... | 10/09/2001 |
| 6291739 | Method for screening of potential anti-epileptic drugs using a Drosophila melanogaster model The invention relates to a method for screening anti-epileptic drugs using fruit fly Drosophila melanogaster by generating single and double mutant lines of K+ channel genes in Drosophila melanogaster, culturing mutant lines on Drosophila mediu... | 09/18/2001 |
| 6284239 | Murine model for human carcinoma A murine model for human breast, ovarian and prostate cancer is provided. The model comprises either an immunodeficient mouse containing human primary breast, ovarian or prostate carcinoma tissue implanted within the gonadal fat pad, or an immunodeficient... | 09/04/2001 |
| 6284944 | Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring This invention discloses a gene-targeted non-human mammal and generational offspring with respect to the gene encoding a mutant protein product of a mutated presenilin 1 gene (PS-1); more specifically, a gene-targeted mouse with respect to the gene sequen... | 09/04/2001 |
| 6278038 | Mammalian melanocortin receptors and uses This invention provides methods and reagents for developing naturally-occurring and synthetic agonists and antagonists specific for a mammalian melanocortin receptor, and the use of such agonists and antagonists for treatment and alleviation of dysfunctio... | 08/21/2001 |
| 6278040 | Receptor-deficient mice and cell lines derived therefrom, and uses thereof In accordance with the present invention, there are provided targeted loss of function mutant mice which express less than endogenous levels of at least one member of the steroid/thyroid superfamily of receptors in at least one specific tissue type. For e... | 08/21/2001 |
| 6274309 | Method for the modulation of acid-sphingomyelinase-related apoptosis The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, ... | 08/14/2001 |
| 6274788 | Bicistronic DNA construct comprising X-myc transgene for use in production of transgenic animal model systems for human hepatocellular carcinoma and transgenic animal model systems so produced The present invention relates to a bicistronic DNA construct comprising X-myc transgene. In particular, the present invention relates to a bicistronic X15-myc transgene capable of expressing truncated X protein and a full-length murine c-myc protein. More... | 08/14/2001 |
| 6271435 | Leukotriene B4 receptor transgenic mice The present invention describes a non-human transgenic mouse that produces in its leukocytes, a recombinant human leukotriene B4 receptor (BLTR), having physiological activity of human BLTR. The transgenic mouse has stably integrated into its g... | 08/07/2001 |
| 6262335 | Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 A transgenic non-human eukaryotic animal whose germ cells and somatic cells contain the amyloid precursor protein sequence introduced into the animal, or an ancestor of the animal, at an embryonic stage.... | 07/17/2001 |
| 6262337 | Transgenic animal with recombinant vascular endothelial growth factor B (VEGF-B DNA) and uses thereof Transgenic animals containing recombinant DNA with modified nucleotide sequence from the vascular endothelial growth factor B (VEGF-B) gene, cells and methods for producing such animals, and methods of using them to assay substances for VEGF-B-like activi... | 07/17/2001 |
| 6255556 | Lean transgenic animals The invention relates to a transgenic animal whose genomic DNA includes a gene comprising a C/EBP promoter operably linked to a DNA sequence encoding a C/EBPଲ polypeptide, wherein the transgenic animal exhibits reduced accumulation of fat in ... | 07/03/2001 |
| 6252132 | Mutant mouse containing a knockout mutation in DNA encoding an endogenous alpha 4 subunit of nicotinic acetylcholine receptor A mutant mouse has germ cells and somatic cells containing a mutation comprising a disruption of the endogenous 댔 subunit of the nicotinic acetylcholine receptor (nAChR) gene, wherein the disrupted 댔 subunit of the nAChR gene results in the ... | 06/26/2001 |
| 6252131 | Transgenic mammal having 5-HT3 transgene overexpression in the CMS The invention relates to transgenic mammals characterized by 5-HT3 receptor over-expression in the central nervous system (CNS) . The mammals have particular utility as models for studying the role of 5-HT3 receptors in the CNS, espe... | 06/26/2001 |
| 6248933 | Cellular basis of vascular-graft stenosis A mouse model for vein graft stenosis useful for identifying compounds which reduce or prevent such stenosis, consisting of a mouse engrafted with an autogenous vein which exhibits detectable stenosis within 30 days of transplantation. Also disclosed are ... | 06/19/2001 |
